In a prespecified interim analysis of a phase 3, randomized, controlled trial, the selective endothelin type A receptor antagonist atrasentan reduced proteinuria in patients with IgA nephropathy, without apparent safety issues. Full ALIGN trial results: https://nej.md/3NzvISW

#MedSky #Nephrology